These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32969742)

  • 1. Non-surgical treatment for hematocele in the bladder associated with ascites puncture in a patient with ovarian hyperstimulation syndrome: a case report.
    Ke X; Lin YH; Wang F
    Postgrad Med; 2021 Jan; 133(1):112-116. PubMed ID: 32969742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ascitic fluid puncture in the treatment of severe forms of ovarian hyperstimulation syndrome].
    Machac S; Dostál J; Oborná I; Zahradnícková V; Brezinová J; Labanová M; Kudela M
    Ceska Gynekol; 2001 Sep; 66(5):333-6. PubMed ID: 11732230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Removal of ascites up to 7.5 liters on one occasion and 45 liters in total may be safe in patients with severe ovarian hyperstimulation syndrome.
    Ozgun MT; Batukan C; Oner G; Uludag S; Aygen EM; Sahin Y
    Gynecol Endocrinol; 2008 Nov; 24(11):656-8. PubMed ID: 19031224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II immunoreactivity is elevated in ascites during severe ovarian hyperstimulation syndrome: implications for pathophysiology and clinical management.
    Delbaere A; Bergmann PJ; Gervy-Decoster C; Staroukine M; Englert Y
    Fertil Steril; 1994 Oct; 62(4):731-7. PubMed ID: 7926081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger and freeze-all strategy in GnRH antagonist protocol; case report and literature review.
    Hajizadeh N; Hosseini S; Salehpour S; Abbasi H; Saheb J
    JBRA Assist Reprod; 2023 Jun; 27(2):325-327. PubMed ID: 36749812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian hyperstimulation syndrome: A review for emergency clinicians.
    Timmons D; Montrief T; Koyfman A; Long B
    Am J Emerg Med; 2019 Aug; 37(8):1577-1584. PubMed ID: 31097257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ovarian hyperstimulation syndrome--prevention and treatment].
    Grønlund LA; Bogstad JW
    Ugeskr Laeger; 1996 Dec; 158(50):7205-9. PubMed ID: 9012033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian hyperstimulation syndrome.
    Budev MM; Arroliga AC; Falcone T
    Crit Care Med; 2005 Oct; 33(10 Suppl):S301-6. PubMed ID: 16215351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The kallikrein-kinin system, but not vascular endothelial growth factor, plays a role in the increased vascular permeability associated with ovarian hyperstimulation syndrome.
    Kobayashi H; Okada Y; Asahina T; Gotoh J; Terao T
    J Mol Endocrinol; 1998 Jun; 20(3):363-74. PubMed ID: 9687159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous abdominal paracentesis for management of late type severe ovarian hyperstimulation syndrome.
    Chan CC; Yin CS; Lan SC; Chen IC; Wu GJ
    J Chin Med Assoc; 2004 Apr; 67(4):197-9. PubMed ID: 15244020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased angiotensin II in ascites during severe ovarian hyperstimulation syndrome: role of early pregnancy and ovarian gonadotropin stimulation.
    Delbaere A; Bergmann PJ; Gervy-Decoster C; Deschodt-Lanckman M; de Maertelaer V; Staroukine M; Camus M; Englert Y
    Fertil Steril; 1997 Jun; 67(6):1038-45. PubMed ID: 9176441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanical thrombectomy for middle cerebral artery occlusion associated with ovarian hyperstimulation syndrome: case report and review of the literature.
    Li X; Zheng J
    Ann Palliat Med; 2021 Mar; 10(3):3504-3509. PubMed ID: 33752418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Some aspects of ovarian hyperstimulation syndrome].
    Kovachev E; Kozovski I; Markova V; Andronov M; Cherneva S; Aleksandrov K
    Akush Ginekol (Sofiia); 2003; 42(6):37-41. PubMed ID: 15067814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the Usefulness of Severity Markers in Women with Ovarian Hyperstimulation Syndrome.
    Petrenko AP; Castelo-Branco C; Marshalov DV; Kuligin AV; Shifman EM; Nesnova ES
    Reprod Sci; 2021 Apr; 28(4):1041-1048. PubMed ID: 33063288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ascites Index - a novel technique to evaluate ascites in ovarian hyperstimulation syndrome: a concept-proof study.
    Szkodziak PR; Czuczwar P; Wrona W; Paszkowski T; Szkodziak F; Woźniak S
    Ginekol Pol; 2018; 89(4):182-8. PubMed ID: 29781072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrasound and hematological changes during early luteal phase in women at high risk for developing ovarian hyperstimulation syndrome.
    Lainas GT; Lainas TG; Venetis CA; Sfontouris IA; Zorzovilis IZ; Alexopoulou E; Tarlatzis BC; Kolibianakis EM
    Ultrasound Obstet Gynecol; 2018 Jan; 51(1):126-133. PubMed ID: 29105961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of luteal GnRH antagonist on moderate and severe early ovarian hyperstimulation syndrome during in vitro fertilization treatment: a prospective cohort study.
    Zeng C; Shang J; Jin AM; Wu PL; Li X; Xue Q
    Arch Gynecol Obstet; 2019 Jul; 300(1):223-233. PubMed ID: 31004220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.